Novartis Raises Peak Sales Forecast for Key Blockbusters Amid Revised Long-Term Growth Guidance
Novartis has increased its combined peak sales forecast for three major drugs—Kesimpta, Scemblix, and Leqvio—to $18 billion, up from a previous estimate of $14 billion. This strategic upgrade aims to mitigate the revenue impact expected from upcoming patent expirations on older products. Despite the higher blockbuster projections, the company issued slightly more conservative long-term guidance, forecasting annual sales growth of 5% through 2031. This is a slight adjustment from its previous target of 5% to 6% through 2030. CEO Vas Narasimhan noted that the revised outlook accounts for anticipated generic competition for the breast cancer treatment Kisqali starting in late 2031.

Tickers: $NVS
Topics: Capital Markets Day Drug Patent Expiry Pharmaceuticals Sales Outlook
Part of the story PPL Corporation Declares Quarterly Dividend and Raises Long-Term EPS Growth Guidance (4 articles)